Acasti Pharma Inc.
| NASDAQ: ACST | Healthcare / Biotechnology / Canada |
| 2.59 | -0.0700 | -2.63% | Vol 55.41K | 1Y Perf -28.49% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 2.54 | ASK | 2.75 | ||
| Open | 2.64 | Previous Close | 2.66 | ||
| Pre-Market | - | After-Market | 2.54 | ||
| - - | -0.05 -1.93% |
| Target Price | 2.30 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -11.20 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★+ 61.16 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | + — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 26.14 | Earnings Rating | Strong Buy | |
| Market Cap | 19.29M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.32 | |
| Beta | 1.38 |
Today's Price Range 2.582.78 | 52W Range 1.725.05 | 5 Year PE Ratio Range -3.70-3.00 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -12.20% | ||
| 1 Month | 23.92% | ||
| 3 Months | -30.38% | ||
| 6 Months | 0.25% | ||
| 1 Year | -28.49% | ||
| 3 Years | -74.31% | ||
| 5 Years | -95.97% | ||
| 10 Years | -99.78% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -103.65 | |||
ROE last 12 Months | -17.40 | |||
ROA (5Y Avg) | -24.76 | |||
ROA last 12 Months | -15.41 | |||
ROC (5Y Avg) | -146.61 | |||
ROC last 12 Months | -15.85 | |||
Return on invested Capital Q | -4.79 | |||
Return on invested Capital Y | -3.45 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.10 | ||||
| 0.31 | ||||
| 450.58 | ||||
| - | ||||
| -2.60 | ||||
| -0.51 | ||||
| 1.74 | ||||
| 2.25 | ||||
| -3 326 570.00 | ||||
| Forward PE | -1.63 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.40 | ||||
| 9.90 | ||||
| 0.00 | ||||
| 0.01 | ||||
| 45.50 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 65.20 | ||||
| -18 944.30 | ||||
| -18 943.50 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | -0.63 | -0.34 | 46.03 |
| Q04 2023 | -0.78 | -0.30 | 61.54 |
| Q03 2023 | -0.78 | -0.54 | 30.77 |
| Q02 2023 | - | -0.66 | - |
| Q01 2023 | - | -0.60 | - |
| Q04 2022 | -0.78 | -0.24 | 69.23 |
| Q03 2022 | -0.10 | -0.11 | -10.00 |
| Q02 2022 | - | 0.04 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.34 | 48.48 | Positive |
| 12/2023 QR | -0.47 | 25.40 | Positive |
| 3/2024 FY | -1.97 | 20.88 | Positive |
| 3/2025 FY | -1.70 | 41.58 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 55.41K |
| Shares Outstanding | 7.45K |
| Shares Float | 5.75M |
| Trades Count | 214 |
| Dollar Volume | 149.05K |
| Avg. Volume | 135.48K |
| Avg. Weekly Volume | 202.74K |
| Avg. Monthly Volume | 121.57K |
| Avg. Quarterly Volume | 82.13K |
Acasti Pharma Inc. (NASDAQ: ACST) stock closed at 2.59 per share at the end of the most recent trading day (a -2.63% change compared to the prior day closing price) with a volume of 55.41K shares and market capitalization of 19.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Acasti Pharma Inc. CEO is Jan D'Alvise.
The one-year performance of Acasti Pharma Inc. stock is -28.49%, while year-to-date (YTD) performance is -13.84%. ACST stock has a five-year performance of -95.97%. Its 52-week range is between 1.72 and 5.0478, which gives ACST stock a 52-week price range ratio of 26.14%
Acasti Pharma Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 0.31, a price-to-sale (PS) ratio of 450.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -15.41%, a ROC of -15.85% and a ROE of -17.40%. The company’s profit margin is -%, its EBITDA margin is -18 943.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Acasti Pharma Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Acasti Pharma Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Acasti Pharma Inc. is Strong Buy (1), with a target price of $2.3, which is -11.20% compared to the current price. The earnings rating for Acasti Pharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acasti Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acasti Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.54, ATR14 : 0.23, CCI20 : 105.62, Chaikin Money Flow : 0.24, MACD : 0.17, Money Flow Index : 88.75, ROC : 32.34, RSI : 62.69, STOCH (14,3) : 67.55, STOCH RSI : 0.74, UO : 62.12, Williams %R : -32.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acasti Pharma Inc. in the last 12-months were:
Acasti Pharma Inc.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes.
CEO: Jan D'Alvise
Telephone: +1 450 687-2262
Address: 3009 Boulevard de la Concorde East,Suite 102, Laval H7E 2B5, QC, CA
Number of employees: 32
